BenzingaAugust 7, 2026 at 9:00 AM NY2 Months Ago

Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

COLLCollegium Pharmaceutical, Inc.

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.

What This Story Means

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga